RBC Cuts PTC Therapeutics (PTCT) Price Target by Nearly 20%

RBC Capital analyst, Simos Simeonidis, cut the PT on PTC Therapeutics (NASDAQ: PTCT) to $9 from $11 after the company disclosed that FDA issued the Refuse-to-File letter because it views both the Phase IIb and the ACT DMD trials as "negative" and not providing "substantial evidence of effectiveness".

The analyst does not see a path forward for ataluren in the US, other than starting a new Phase III trial and the European approval is also at risk.

The analyst uses a sum-of-the-parts methodology to value PTC Therapeutics shares at $9/share and estimates the probability adjusted NPV as:

1) Translarna sales in DMD in the EU (50% probability) ($6/share)

2) Translarna sales in DMD in JPN/ROW (30% probability) ($1.50/share)

3) the company’s projected net cash position ($1.50/share)

For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.

Shares of PTC Therapeutics closed at $7.98 yesterday.

You May Also Be Interested In

• PTC Therapeutics (PTCT) PT Raised to $137 at Cantor Fitzgerald on ST-920 Acquisition
• Cal-Maine Foods (CALM) PT Lowered to $80 at Stephens
• BMO Capital Starts Tenet Healthcare (THC) at Market Perform